# A Study of Tarceva (Erlotinib) and Avastin (Bevacizumab) in Patients With Advanced or Metastatic Liver Cancer.

> **NCT00605722** · PHASE2 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 51 (actual)

## Conditions studied

- Liver Cancer

## Interventions

- **DRUG:** bevacizumab (Avastin)
- **DRUG:** erlotinib (Tarceva)

## Key facts

- **NCT ID:** NCT00605722
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-03
- **Primary completion:** 2010-09
- **Final completion:** 2010-09
- **Target enrollment:** 51 (ACTUAL)
- **Last updated:** 2014-07-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00605722

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00605722, "A Study of Tarceva (Erlotinib) and Avastin (Bevacizumab) in Patients With Advanced or Metastatic Liver Cancer.". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00605722. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*